Editors from across the U.S. learned that Heel’s homeopathic combination drugs’ quality and safety is equal to conventional drugs, said Cliff Clive, CEO of Heel Inc.
Albuquerque, NM (PRWEB) October 23, 2012
14 retail and scientific editors from all over the United States joined a meeting on October 6th at Heel Inc. in Albuquerque, NM, that spotlighted important aspects of the increasing popularity of combination drugs based mainly on natural substances. Specialists from natural healthcare manufacturer, Heel Inc., and the St Laurent Institute, a genomics research center discussed quality aspects, regulatory framework, scientific background and economic implications of Heel’s homeopathic combination drugs with the editors.
Editors from across the U.S. learned that Heel’s homeopathic combination drugs’ quality and safety is equal to conventional drugs, following or exceeding all regulatory requirements such as a cGMP production site or an advanced Pharmacovigilance system, said Cliff Clive, CEO of Heel Inc.
As a surprise to some participants, the scientific evidence for many homeopathic combination preparations show rock solid data in both clinical and pre-clinical research proving efficacy and sometimes even as effective as conventional drugs. Philipp Kapranov, PhD., Senior Research Manager from the St. Laurent Institute presented data from a deep sequencing genomics project with a Heel product. “The genomic profile clearly shows the strong modulating effect that this drug has on multiple parts of the inflammation cascade,” said Kapranov. “With deep sequencing genomics, we can for the first time see on a gene level where, exactly, this homeopathic drug modulates the inflammatory processes in a multi-targeted fashion. This way we can provide a rationale for its mode of action.”
Alta Smit, M.D., Director of Global Medicine and Research at Heel headquarters in Germany presented a high-level clinical study (RCT) that proved the parity of the natural pain relief product Traumeel S®, (the European formula which differs only slightly from the USA formula) compared to a Diclofenac* preparation (NSAID). Dr. Smit also expanded on the underlying principles of homeopathic combination preparations that due to their multi-target abilities help to minimize side-effects. “We take the best from both worlds,” commented Smit. “Hard scientific evidence on the one hand and an individualized therapy approach on the other hand helps us to contribute to a patient-centered, integrative medicine. Heel products show efficacy and have a very favorable side effect profile.”
As an example for this, Director of Marketing, Ann Thompson, expanded on chronic pain management– an issue that over 100 million U.S. citizens are concerned with and that causes a total annual incremental cost of health care ranging from $560 billion to $635 billion. By using the natural pain relief product, Traumeel®, relief can come without frequent side effects which can be bothersome or even serious. This is just one out of many indications where homeopathic drugs offer a huge potential not only to improve patient care but also to reduce health costs.
*Diclofenac is a prescriptive only topical ointment in the U.S.
Heel is a science-based pharmaceutical company that develops, manufactures and distributes medicines based on natural substances. Celebrating over 75 years, the company is a pioneer in the field of science-based homeopathic research on natural medicine and a global leader for the production of homeopathic, combination medications. With the help of its unique therapeutic concept based on Bioregulatory Medicine, Heel is working to build the bridge between conventional medicine and homeopathy. Heel medicines are available through physicians and licensed health care practitioners, independent pharmacies, retailers and fine natural product stores throughout the United States. For more information on other Heel products and their use please visit http://www.heelusa.com.